Ramy Toma, MD
Internal Medicine · Birmingham, ALNPI 1083766604
Payments from drug & device makers
Across 71,352 payments — averaging $70.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$4.5M
- Sanofi Pasteur Inc.$579K
- Sandoz$13K
- Novo Nordisk$1K
- GSK$624
- Lilly USA, LLC$593
- plus $3K from 29 others
Across 38 payments — averaging $275.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi Pasteur Inc.$10K
What the payments were for
- Food & beverage$5,73798%
- Education$1052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 70,966 | $4,467,874 |
| Sanofi Pasteur Inc. | 39 | $578,685 |
| Sandoz | 1 | $12,511 |
| Novo Nordisk | 79 | $1,133 |
| GSK | 36 | $624 |
| Lilly USA, LLC | 34 | $593 |
| Pfizer | 32 | $521 |
| Amgen | 21 | $371 |
| Astellas Pharma US Inc | 12 | $316 |
| Johnson & Johnson | 16 | $216 |
| Dexcom, Inc. | 9 | $206 |
| Boehringer Ingelheim | 12 | $179 |
| AstraZeneca | 12 | $174 |
| Bayer | 11 | $173 |
| E.r. Squibb & Sons, L.L.C. | 9 | $158 |
| Abbott | 8 | $152 |
| Corcept Therapeutics | 7 | $135 |
| Merck | 8 | $131 |
| Novartis | 5 | $103 |
| Exact Sciences | 6 | $103 |
| Axsome Therapeutics, Inc. | 1 | $70 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| Lundbeck LLC | 3 | $56 |
| AbbVie(2 entities) | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Ironwood Pharmaceuticals, Inc | 2 | $36 |
| Radius Health, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Mylan Specialty L.p. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $17 |
| Vertex | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$5,064,912 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 323 | $416,432 |
| MounjaroTirzepatide | 203 | $270,562 |
| JardianceEmpagliflozin | 260 | $267,724 |
| EliquisApixaban | 210 | $169,594 |
| TrulicityDulaglutide | 103 | $132,146 |
| JanuviaSitagliptin Phosphate | 111 | $103,651 |
| FarxigaDapagliflozin Propanediol | 102 | $100,030 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $91,695 |
| MyrbetriqMirabegron | 89 | $83,143 |
| Tresiba Flextouch U-200Insulin Degludec | 81 | $79,758 |
| EntrestoSacubitril/Valsartan | 51 | $65,701 |
| LinzessLinaclotide | 56 | $49,998 |
| XareltoRivaroxaban | 43 | $37,331 |
| TradjentaLinagliptin | 28 | $35,504 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $32,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,133 | $440,894338 claims |
| Lilly USA, LLCMounjaro, Trulicity | $593 | $402,708306 claims |
| Boehringer IngelheimJardiance, Tradjenta | $179 | $303,228288 claims |
| PfizerEliquis | $521 | $169,594210 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $624 | $155,861217 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $174 | $112,513120 claims |
| MerckJanuvia | $131 | $103,651111 claims |
| Astellas Pharma US IncMyrbetriq | $316 | $83,14389 claims |
| NovartisEntresto | $103 | $65,70151 claims |
| AbbVieLinzess, Namzaric | $51 | $60,82269 claims |
| Johnson & JohnsonXarelto, Invokana | $216 | $44,66554 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $7,16411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
- Kevin RiggsBirmingham$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.